NaMuscla reduces myotonia symptoms in the people with NDM, resulting in a significant improvement in quality of life and other functional and clinical outcomes for patients.
Lupin Signs Distribution Agreement with Medis for Orphan Drug NaMuscla Agreement enables expanded patient access of the only EU-approved treatment for myotonia symptoms in non-dystrophic myotonic
The agreement enables expanded patient access to the only EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders in Central and Eastern European territories
FOR UK MEDICAL AND TRADE MEDIA ONLY Lupin's Namuscla (mexiletine) is recommended by NICE for treatment of symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM) Slough